SPRY — ARS Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1671858 ·
Last close
$4.08
Market Cap
$405.75M
52W High
$13.15
52W Low
$4.02
ADV30
1,648,633
Next earnings
2026-11-10

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 33,658,000 20,812,000 -61,465,000 -62,339,000 249,495,000 8,163,000 236,983,000
Mar 2026 22,681,000 16,395,000 -60,145,000 -60,618,000 287,571,000 24,321,000 226,263,000
Dec 2025 28,087,000 21,933,000 -41,465,000 -41,324,000 327,652,000 41,317,000 213,394,000
Sep 2025 32,501,000 24,310,000 -53,192,000 -51,151,000 372,803,000 59,557,000 225,148,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-175,070,000
Investing CF
$55,495,000
Financing CF
$104,032,000
CapEx
$-641,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.94
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-355,221,000
Inventory
$8,817,000
Receivables
$28,662,000
ST Investments
$176,648,000
EBIT TTM
$-189,779,000
Pretax Income TTM
$-198,056,000
Interest Exp TTM
$2,441,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$116,927,000
EBITDA
$-214,646,000
Free Cash Flow
$-117,704,248
Enterprise Value
$501,127,360
Total Cash
$143,844,992
Total Debt
$171,603,008
Shares Out
99,447,343
Trailing EPS
$-2.18
Book Value
$0.13
ROE
-210.3%
ROA
-48.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 84,278,000 -179,448,000 -171,298,000 327,652,000 213,394,000 114,258,000 -170,866,000
Dec 2024 89,149,000 -3,083,000 7,998,000 351,153,000 94,355,000 256,798,000 13,548,000
Dec 2023 30,000 -67,520,000 -54,365,000 233,188,000 2,428,000 230,760,000 -59,266,000
Dec 2022 1,316,000 -35,516,000 -34,682,000 281,435,000 8,549,000 272,886,000 -40,078,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.90

Max Pain — expiry 2026-10-16

max pain strike: $5.00 · spot: $4.07 · call oi: 1,143 · put oi: 96
Expected Move to 2026-10-16: ±$1.03 (25.22%) — implied range $3.04 – $5.09 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RLMD RELMADA THERAPEUTICS, INC. $408.55M $3.83 —
CTNM Contineum Therapeutics, Inc. $413.96M $12.56 —
AVIR Atea Pharmaceuticals, Inc. $414.66M $5.17 —
IRD Opus Genetics, Inc. $396.01M $4.76 —
ARCT Arcturus Therapeutics Holdings Inc. $393.66M $13.85 —

News headlines (Yahoo Finance, 1h cache)

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-09-01 20:01 · Yahoo
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
2026-08-20 13:55 · Yahoo
ARS Pharmaceuticals Q2 Earnings Call Highlights
2026-08-14 03:04 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 21:35 · Yahoo
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
2026-08-13 20:01 · Yahoo
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
2026-08-03 11:30 · Yahoo
ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO
2026-07-15 15:42 · Yahoo
ARS Pharmaceuticals Announces CEO Succession
2026-07-07 20:30 · Yahoo
ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices
2026-06-29 02:06 · Yahoo
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today
2026-06-25 01:43 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.